BTOG 2023 | Neoadjuvant therapy and the impact on laboratories

Angeles Montero-Fernandez, MD, PhD, Manchester University NHS Foundation Trust, Manchester, UK, explains that the improvement in patient outcomes that has become evident with the implementation of immunotherapy and neoadjuvant treatments necessitates changes to clinics and labs. Though these changes are challenging to implement, they are essential and certain. Dr Montero also stresses the importance of open communication between researchers studying the molecular specifics of tumors and those involved in tissue diagnosis and therapeutic response, to form a united picture which will translate into improved results. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.